SUMMARY
The absence of cancer-restricted surface markers is a major impediment to antigen-specific immunotherapy using chimeric antigen receptor (CAR) T cells. For example, targeting the canonical myeloid marker CD33 in acute myeloid leukemia (AML) results in toxicity from destruction of normal myeloid cells. We hypothesized that a leukemia-specific antigen could be created by deleting CD33 from normal hematopoietic stem and progenitor cells (HSPCs), thereby generating a hematopoietic system resistant to CD33-targeted therapy and enabling specific targeting of AML with CAR T cells. We generated CD33-deficient human HSPCs and demonstrated normal engraftment and differentiation in immunodeficient mice. Autologous CD33 KO HSPC transplantation in rhesus macaques demonstrated long-term multilineage engraftment of gene-edited cells with normal myeloid function. CD33-deficient cells were impervious to CD33-targeting CAR T cells, allowing for efficient elimination of leukemia without myelotoxicity. These studies illuminate a novel approach to antigen-specific immunotherapy by genetically engineering the host to avoid on-target, off-tumor toxicity.
INTRODUCTION
Recent advances in cancer immunotherapy with chimeric antigen receptor (CAR) T cells have enabled eradication of cells expressing a specific surface antigen. While this approach has been successful in targeting CD19 in B cell neoplasms (Davila et al., 2014; Kochenderfer et al., 2015; Lee et al., 2015; Maude et al., 2014; Turtle et al., 2016) , it does not discriminate between normal and malignant B cells, and thus, the feasibility of this therapy rests on the tolerability of prolonged B cell aplasia. However, most malignancies do not have an expendable normal tissue counterpart, and whether the success of CAR T cells can be extrapolated beyond B cell neoplasms will depend on the ability to develop strategies to mitigate toxicity to normal cells.
The majority of acute myeloid leukemia (AML) patients relapse despite intensive therapy. AML cell surface antigens are shared with normal myeloid progenitors (Levine et al., 2015; Taussig et al., 2005) ; therefore, targeting AML also generates toxicity to the myeloid system (Gill et al., 2014; Leong et al., 2017; Mardiros et al., 2013; Pizzitola et al., 2014; Tashiro et al., 2017) . While strategies to produce transient CAR T cells are being explored in clinical trials to avoid long-term myeloablation while targeting AML (e.g., #NCT03126864, #NCT02159495), this negates a fundamental strength of this therapy-namely, its long-term anti-tumor immune surveillance. Therefore, in the absence of a truly AML-specific antigen, novel approaches are required to definitively target AML while sparing normal hematopoiesis. 
(legend continued on next page)
Here, we propose a new paradigm for antigen-specific immunotherapy against myeloid neoplasms in which potent antigendirected therapy can be administered without causing prolonged myeloid aplasia. We use gene-edited hematopoietic stem and progenitor cells (HSPCs) to regenerate an antigen-negative myeloid system that is resistant to antigen-targeting therapy.
CD33 is a member of the sialic acid-binding immunoglobulinlike lectin (siglec) family. CD33 is expressed on all normal myeloid cells downstream of the common myeloid progenitor and is used as both a diagnostic marker and a therapeutic target for AML (Laszlo et al., 2014) . We show here that CD33 knockout (KO) HSPC can generate functional hematopoiesis that is resistant to CD33-targeted AML therapy in two relevant preclinical models and provide evidence for the clinical feasibility and efficacy of combining allogeneic transplantation of CD33 KO HSPCs with CD33 CAR T therapy to treat patients with otherwise incurable AML.
RESULTS

Human CD33 KO HSPC Remain Functional
We disrupted the CD33 gene in primary human CD34+ cells using truncated guide RNAs (gRNAs) (Fu et al., 2014) , which have been reported to increase specificity of gene editing. We found that truncated gRNAs increased the efficacy of CD33 KO compared to their full-length counterparts ( Figure 1A ). Initially, we achieved around 40% KO in primary CD34+ cells ( Figure 1B ), of which a large proportion of mutations consisted of a single adenine (A) nucleotide insertion ( Figure 1C ). We further enhanced editing by adding a single-stranded oligodeoxynucleotide (ssODN) template containing the A insertion, leading to dose-dependent increase in frequency of KO ( Figure 1D ). Subsequent experiments were performed via transfection of Cas9 protein complexed with a truncated gRNA targeting CD33 and the ssODN template to generate CD33 KO HSPCs, while control HSPCs were treated with Cas9 and a gRNA targeting the irrelevant gene EMX1 ( Figure 1E ). In vitro differentiated CD33 KO HSPCs had markedly reduced levels of surface CD33 protein expression (27% ± 4%) compared to controls (92% ± 3%) ( Figure 1F ) without impairment of growth or differentiation ( Figures 1G-1J ). High frequency of mutations in the CD33 gene was confirmed by tracking of indels by decomposition (TIDE) and next-generation sequencing (Figures 1K and 1L) .
We injected NOD/SCID/IL2rg null (NSG) mice with control (Cas9/EMX1-gRNA) or CD33 KO (Cas9/CD33-gRNA/ssODN) HSPCs and followed human cell engraftment in the peripheral blood over time ( Figure 2A ). We found that human monocytes in the peripheral blood of mice engrafted with CD33 KO HSPC had the expected diminished expression of CD33 that was sustained over time ( Figure 2B ). Total human CD33+ cells were significantly decreased in the CD33 KO HSPC-engrafted mice compared to controls, while numbers of total human CD45+ cells, as well as myeloid subsets (CD11b+ and CD14+ cells), were identical between the two groups ( Figure 2C ). Bone marrow analysis confirmed similar levels of human engraftment and differentiation between control and CD33 KO HSPC-engrafted mice, while decreased expression of CD33 was observed in myeloid cells. Levels of the most primitive (CD34+38À) and more mature (CD34+38+) human HSPCs in the marrow were not significantly different between the two groups ( Figure 2D ). To document that CD33 KO HSPCs retain long-term repopulating function, we harvested bone marrow cells from mice engrafted with control or CD33 KO HSPCs after 16 weeks and transferred these cells into secondary recipients. Bone marrow analysis of the secondary recipients after 12 additional weeks showed sustained human engraftment, while CD33 expression remained diminished in CD33 KO HSPC recipients ( Figure 2E ), and PCR confirmed the presence of mutations in CD33 at similar levels to the initial infusion product ( Figure 2F ). These results indicate that CD33 KO occurred in cells capable of long-term and serial engraftment.
We next performed several studies to probe the function of CD33 KO myeloid cells. Human cells in the marrow of mice (B) Human CD34+ cells were electroporated with Cas9 protein and truncated CD33-targeting gRNA4 (from A). Surface CD33 protein expression was assessed by flow cytometry (left) and DNA mutations were quantified by SURVEYOR assay (right) following 7 days of in vitro culture. (C) Sanger sequencing of individual alleles reveals a high proportion of mutations containing a single A insertion (top); representative chromatogram is shown (bottom). (D) A single-stranded oligodeoxynucleotide (ssODN) was designed to contain 99-bp homology arms around the gRNA cut site and the A insertion mutation (top). CD34+ cells were electroporated with Cas9 protein/gRNA and different concentrations of the ssODN, after which CD33 expression was assessed by flow cytometry (bottom left) following 7 days of culture. Addition of the ssODN increases the frequency of CD33 mutations in three different donors in three independent experiments (bottom right ; paired t test). (E) Experimental schema: human CD34+ cells were electroporated with either Cas9 complexed with EMX1-gRNA (Control) or Cas9/CD33-gRNA4 and the ssODN (CD33 KO) and cultured for 7 days. (F) Cultured CD33 KO CD34+ cells have decreased levels of surface CD33 expression by flow cytometry compared to controls (n = 21, 18 different donors, 14 independent experiments). Representative flow cytometry plot is shown on right (unpaired t test). (G) Control and CD33 KO CD34+ cells maintained in StemSpan SFEM with SCF (100 ng/mL), Flt3L (100 ng/mL), TPO (50 ng/mL), and IL-6 (50 ng/uL) show similar growth kinetics (n = 3, 3 donors, 2 independent experiments; unpaired t test). (H) CD34+ cells were plated in Methocult H4435 1 day after electroporation and scored for colony formation after 14 days (n = 3, 3 donors, 2 independent experiments; unpaired t test). (I) Methocult colonies were resuspended in liquid media, and flow cytometry was performed for the myeloid markers CD33, CD14, and CD11b (n = 3, 3 donors, 2 independent experiments; unpaired t test). 5 control or CD33 KO HSPCs, and human CD45+ hematopoiesis was analyzed over time. (B) Longitudinal monitoring of human CD14+ monocytes show a decreased fraction of CD33+ monocytes in CD33 KO HSPC-engrafted mice compared to controls. Representative flow plot is shown on right. ****p < 0.0001 (unpaired t test). (C) CD33 KO HSPC-engrafted mice have significantly decreased numbers of CD33+ cells in the peripheral blood at 12 weeks post transplant, while total numbers of cells expressing CD45, CD14, and CD11b are similar to controls (n = 57 mice, 4 independent experiments, 5 donors). ns, not significant (p > 0.05); ***p < 0.001 (unpaired t test).
(legend continued on next page) engrafted with CD33 KO HSPCs were morphologically normal, and absence of CD33 was confirmed by immunocytochemistry ( Figure 3A) . We interrogated the ability of in vitro differentiated CD33 KO myeloid cells to perform phagocytosis, generate reactive oxygen species, and secrete inflammatory cytokines/ chemokines ( Figures 3B-3D ). We used HSPCs that had approximately 50% CD33 KO and gated on the CD33+ and CD33À cells separately, using the CD33+ cells as an internal control while also comparing to control HSPCs. We also performed these studies on cells sorted for CD33+/À expression to exclude any non-cell autonomous function of CD33 ( Figure S1 ). We found no significant difference in any of our studies when comparing the function of CD33À myeloid cells to control cells that were uniformly CD33+. We also performed high-dimensional functional profiling of control and CD33 KO HSPCs using mass cytometry (Behbehani et al., 2015; Levine et al., 2015) . Other than the expected differences in CD33 expression, we found no differences in the differentiation profile between control and CD33 KO cells by SPADE analysis ( Figure S2A ). Cells were exposed to relevant ex vivo perturbations (granulocyte-macrophage colonystimulator factor [GM-CSF] [TPO] ) and activation of intracellular signaling pathways in relevant hematopoietic subpopulations was quantified. Remarkably, control and CD33 KO cells responded identically to external stimuli, and within the CD33 KO cell population, both the CD33+ and CD33À cells responded to the same degree (Figures 3E , S2B, and S2C).
To exclude a major impact of CD33 loss on downstream gene expression, we performed RNA sequencing (RNA-seq) of CD33 KO myeloid cells and controls, which showed a highly concordant gene expression profile. Paired analysis of matched control and CD33 KO samples showed that CD33 was the most significantly differentially expressed gene ( Figure 3F ).
Finally, we performed studies in mice engrafted with CD33 KO or control human hematopoiesis to evaluate their functional properties in vivo. To model gram-negative sepsis, we injected mice with lipopolysaccharide, which induced high levels of human inflammatory cytokines in the serum with no difference detected between control and CD33 KO ( Figure 3G ). We also challenged the mice with G-CSF, which induced an equivalent increase of human neutrophils (CD66b+) and monocytes (CD14+) in the peripheral circulation, while in the CD33 KO HSPC-engrafted mice, both CD33+ and CD33À myeloid cells increased to the same degree ( Figure 3H ). These observations confirmed our hypothesis that human myeloid cells would tolerate loss of CD33.
For additional evidence that CD33 may be redundant in human health, we examined several databases of naturally occurring homozygous loss-of-function mutations in large population cohorts (Lek et al., 2016; Narasimhan et al., 2016; Saleheen et al., 2017; Sulem et al., 2015) . We found 51 individuals reported to have homozygous loss-of-function mutations in the CD33 gene (Table S1 ), the majority (86%) of which consisted of a deletion of four base pairs in exon 3 (rs201074739), resulting in a frameshift mutation in all protein-coding transcripts of CD33. In the Iceland cohort (Sulem et al., 2015) , four of these individuals were reported to have reached 64 to 93 years of age.
To evaluate whether our CRISPR/Cas9-based CD33 KO system would cause any off-target mutagenesis, we performed cytogenetic analysis of multiple control/CD33 KO primary samples for gross chromosomal rearrangements, which were not detected ( Figure S3A ). We further analyzed six donor samples by PCR and found that all showed evidence of deletion of the 14-kb fragment between CD33 and SIGLEC22P, a pseudogene that has 100% homology with CD33 at the gRNA binding site (Figure S3B ). These two genes are directly adjacent to each other, with no known genetic element in the intervening sequence. We then performed targeted deep sequencing of the top 10 predicted off-target sites in primary CD34+ cells after CD33 KO in comparison with control cells from the same donor ( Figure S3C ). In all samples, the on-target site, CD33, had high levels of mutations (86% ± 4%), and SIGLEC22P harbored a similar extent of mutations as the target gene (85% ± 9%). Only one additional site, SIGLEC6, was found to have low-frequency mutations (0.41%-1.72%) in three of the five donors evaluated.
As a more comprehensive screen for all potential off-target mutation sites in a genome-wide unbiased manner, we performed circularization for in vitro reporting of cleavage effects by sequencing (CIRCLE-seq) (Tsai et al., 2017) on genomic DNA from human primary cells and identified 95 sites cleaved by the Cas9/CD33-gRNA complex in vitro (Figures S3D and S3E) . We then performed targeted deep sequencing in primary CD34+ cells in 16 sites that had a high read count on CIRCLEseq and/or had a three-or-less nucleotide mismatch to the ontarget sequence. Most of the sites had no detectable mutations in primary cells.
Transplantation of CD33 KO HSPCs in Rhesus Macaques
We next turned to a non-human primate (NHP) model to rigorously evaluate the long-term effects and functional consequences of (D) Bone marrow harvested from mice after 12-16 weeks of HSPC engraftment shows equivalent levels of human CD45+ cell engraftment, with differentiation into both lymphoid (B cells: CD19+, T cells: CD3+) and myeloid lineages, while myeloid cells have markedly decreased levels of CD33. Human hematopoietic stem (CD34+38À) and progenitor (CD34+38+) cell levels are comparable between control and CD33 KO HSPC-engrafted mice. ****p < 0.0001; ns, not significant (p > 0.05) (unpaired t test) (n = 20 mice, 3 independent experiments, 3 donors). (E) Marrow was harvested from mice engrafted with control or CD33 KO HSPCs after 16 weeks (primary), and human CD45+ cells were purified and injected into secondary recipients (secondary; each donor transplanted into a single recipient) and monitored for an additional 12 weeks. Both groups of mice show sustained human hematopoiesis after long-term engraftment (left), and the CD33 KO HSPC-engrafted group had persistent loss of CD33 expression (right; n = 12 mice, 3 independent experiments, 4 donors). ****p < 0.0001; ns, not significant (p > 0.05) (unpaired t test). (F) PCR performed on marrow from secondary recipients confirms continued presence of mutations in the CD33 gene by SURVEYOR assay (left). Mutation levels as quantified by TIDE are similar between the initial infusion product (input) and the bone marrow 28 weeks after transplantation (output; right). ns, not significant (p > 0.05) (paired t test). All data are represented as mean ± SD. CRISPR/Cas9-mediated CD33 KO on HSPCs. CD33 was expressed uniformly on over 95% of neutrophils from both rhesus macaques (RMs) and humans, but expression on monocytes was more heterogeneous in RMs ( Figure S4A) ; thus, we focused on the neutrophil population for further studies. Of note, following in vitro expansion in the presence of myeloid cytokines for 10 days, virtually all human CD34+ cells expressed CD33, in contrast to only 20%-30% of cultured RM CD34+ cells (Figure S4B) , highlighting some species-specific differences in CD33 expression.
We identified gRNA sequences targeting sites in exons 2 or 3 of the RM CD33 gene that showed activity in vitro in primary RM CD34+ cells. As levels of CD33 KO in RM CD34+ cells were not as robust as in human cells, we used two methods to increase the frequency of mutations: first, we used two gRNAs in combination, and second, we added a ssODN template analogous to that used in the human studies ( Figures S4C and S4D ). Both approaches were utilized in in vivo studies.
We performed apheresis collection and purification of CD34+ HSPCs in two monkeys, ZL38 and ZL33. Autologous CD34+ HPSCs were electroporated with the CD33-targeting gRNAs/ Cas9 protein complexes and ssODNs homologous to the targeted exons and reinfused into the donor following myeloablative total body irradiation ( Figure 4A ). Figure 4B summarizes transplantation parameters for ZL38 and ZL33. Following autologous transplantation of CD33 KO HSPCs, both RMs engrafted promptly without transplantation-related complications. The pattern and rate of recovery of blood counts, including neutrophils and monocytes, was similar in these two animals compared to three historical controls (Wu et al., 2014 (Wu et al., , 2018 (Figures S5A-S5D ). Furthermore, we found similar morphology and myeloperoxidase (MPO) expression in the marrow between ZL38/ZL33 and a control RM that underwent autologous transplantation with lentivirally transduced CD34+ cells ( Figure S5E ).
ZL38 received cells exposed to gRNAs targeting both exon 2 and exon 3, while ZL33 received cells exposed to the exon-2-targeting gRNA only. An aliquot of the HSPC infusion product showed 17% and 36% homozygous KO colony-forming units (CFUs) in ZL38 and ZL33, respectively ( Figure 4C ). We were able to detect clear populations of CD33-negative neutrophils in the blood of both animals by flow cytometry following engraftment ( Figure 4D ). The levels were highest at 2-4 weeks following transplantation and then decreased, plateauing by 6 months post transplantation at levels of 3%-6% in both animals, with no further significant decrease by 12 and 17 months post transplantation in ZL38 and ZL33, respectively. This pattern suggests more efficient editing of short-term progenitors than longterm HSPCs.
To confirm editing at the CD33 target sequences, we tracked the edited allelic fractions over time using targeted deep sequencing to identify the specific indels introduced by CRISPR/Cas9. In ZL38, two gRNAs were used, and the target sites of each were sequenced individually. The frequencies of indels in the infusion product were 12% and 7% for exons 2 and 3, respectively, and highest levels were observed at 1 month in vivo, then plateaued at a level of about 1% for each exon over time ( Figure 4E ). The most frequent indel at both exon 2 and exon 3 targets was an A insertion at the Cas9 cut site, presumably resulting from recombination with the ssODN template. Large deletions of the area between exon 2 and exon 3 were detected in approximately 2% of the alleles, and Sanger sequencing confirmed that this fragment represented fusions between sequences upstream of the exon 2 cut site and downstream of the exon 3 cut site ( Figure 4F ). The frequency of the deletion between the two gRNA cut sites of the CD33 gene was quantified TPO, Flt3L, , and GM-CSF for 7-14 days prior to functional assays. CD33+/À cells within the CD33 KO group were gated separately by flow cytometry for analysis as compared to ungated control cells, which are all CD33+. (B) In vitro-differentiated CD33 KO myeloid cells retain phagocytosis ability as measured by internalization of pHrodo green E. coli bioparticles (n = 6 per group, one-way ANOVA). (C) Levels of reactive oxygen species (ROS) production after phorbol myristate acetate (PMA) stimulation are similar among the three groups of cells. ROS production was measured by fluorescence of CellROX Green reagent (n = 5 per group, one-way ANOVA). (D) Cytokine production as measured by intracellular staining is not significantly different in CD33À cells as compared to internal CD33+ or unedited controls, whether under basal conditions or after lipopolysaccharide (LPS) stimulation (n = 5 per group, one-way ANOVA). (E) Cells were treated with the indicated stimuli (GM-CSF, G-CSF, IFNa, IFNg, IL-4, IL-6, LPS, PMA/ionomycin, or TPO) for 15 min followed by mass cytometry analysis using antibodies to 20 surface markers and 10 phosphoproteins for a comprehensive analysis of signaling pathways (n = 3 per group). Control (ungated) and CD33+/À gated cells within the CD33 KO cell group display identical signaling profiles within the myeloid progenitor population as defined by SPADE analysis (see Figure S2 for SPADE diagram). Representative plots of CD33 KO cells show that CD33À and residual CD33+ cell populations respond to the indicated stimuli to the same degree (gated on live CD64+HLAÀDR+ events). (F) Gene expression profile of in vitro-differentiated control and CD33 KO CD34+ cells (with 70%-85% CD33 KO) were analyzed by RNA-seq (n = 5 per group). Log-scale scatterplot of mean gene expression values of control and CD33 KO samples show high correlation between the two groups (left), while volcano plot shows CD33 as the most significant differentially expressed gene (right). (G) LPS injection induces similar levels of human inflammatory cytokine secretion in the serum of mice engrafted with control or CD33 KO HSPC (control: n = 10, CD33 KO: n = 12) (unpaired t test). (H) NSG mice engrafted with control or CD33 KO HSPCs were injected with G-CSF and numbers of peripheral blood human myeloid cells were evaluated before and after treatment (n = 9 per group, 2 donors, 2 independent experiments). Representative flow cytometry plot shows increase in both %CD14+CD33+ and %CD14+CD33À cells in the CD33 KO group after G-CSF injection (left), gating on single live human CD45+ events. Increased numbers of neutrophils (CD66b+) and monocytes (CD14+) were detected in the peripheral blood of both cohorts after G-CSF, and within the CD33 KO HSPC-engrafted mice, no difference in CD33+ or CD33À cell populations was detected (right) (one-way ANOVA). ns, not significant (p > 0.05). See also Figures S1, S2 , and S3 and Table S1 . (legend continued on next page)
by digital droplet PCR (ddPCR). Similar to flow cytometry or deep sequencing data, the CD33 deletion frequency dropped early during the post-transplantation period, and a deletion rate of 2%-4% persisted long term ( Figure 4G ). ZL33 was treated with a single gRNA and exhibited the same pattern of higher initial engraftment with edited cells followed by stabilization at a level of approximately 4%, again with the A insertion most prominent ( Figure 4H ). We analyzed indel frequency in CFUs grown from the marrow of ZL33 at 4.5 months post transplant and observed 5% homozygous and 3% heterozygous mutations within the range observed in circulating cells at the same time point ( Figure 4I ). We sorted neutrophils based on CD33 expression. As expected, the frequency of indels in purified CD33-negative neutrophils was significantly higher than in the bulk neutrophil population, and CD33-positive neutrophils had the fewest indels (Figures S6A and S6B) . We performed studies to assess maturation and differentiation of CD33 KO HSPCs in ZL33. First, we examined the distribution of CD33 mutations across purified cells from various hematopoietic lineages in the blood. All showed similar CD33 indel frequencies, suggesting that CD33 KO HSPCs maintain their ability to differentiate to all lineages ( Figure S6C ). We analyzed CD33 mutations in CD34+ cells, CD34À cells, and granulocytes from marrow aspirates and compared to CD33 mutations in circulating neutrophils and found indel frequencies to be similar between progenitors and mature cells in the marrow or in the circulation ( Figure 4H ), suggesting normal myeloid maturation and release ( Figure S6D ). In summary, CD33 KO HSPCs successfully engrafted and maintained long-term stable repopulation capacity without evidence of perturbation with respect to hematopoietic lineage differentiation capacity.
We next assessed the physiologic functions of CD11b+ CD33À and CD11b+CD33+ neutrophils purified from the blood of ZL38 and ZL33. There were no differences in morphology between CD33+ and CD33À bands and neutrophils from the geneedited animals, and all samples were similar to neutrophils from control RM ( Figure 5A ). We also studied phagocytosis and reactive oxygen species (ROS) production capabilities of CD33+ and CD33À neutrophils and found no differences (Figures 5B and 5C) . Apoptosis and necrosis were also similar between CD33+ and CD33À neutrophils ( Figure 5D ). Finally, we tested neutrophil chemotaxis and found no defect in chemotaxis of CD33À neutrophils at baseline or toward formyl-methionyl-leucyl-phenylalanine (fMLF), a prototypic chemotactic factor ( Figure 5E ). Taken together, our data suggest that CD33-deficient myeloid progenitors and mature neutrophils traffic and function normally and that CD33 KO HSPCs should be able to safely maintain myelopoiesis.
CD33 KO HSPCs Are Resistant to CD33-Targeted Therapy
To demonstrate resistance of CD33 KO HSPCs to CD33-targeted therapy, we turned to our human xenograft models. CAR T cells targeting CD33 (CART33) have been shown to eradicate AML while also eliminating normal CD33+ myeloid cells (Dutour et al., 2012; Kenderian et al., 2015; Pizzitola et al., 2014; Wang et al., 2015) . We treated mice engrafted with control or CD33 KO HSPCs with autologous T cells transduced with lentivirus encoding an anti-CD33-41BB-CD3z CAR as previously reported (Kenderian et al., 2015) ( Figure 6A ). As expected, all CD33+ cells were eliminated in both groups, leading to complete disappearance of CD14+ human monocytes in the control mice ( Figure 6B ). Crucially, in the mice engrafted with CD33 KO HSPCs, CD14+ cells were retained in the peripheral blood, spleen, and marrow (Figures 6B and 6C) . We also found sparing of human hematopoietic stem cells (CD34+38À) and progenitors (CD34+38+) in the marrow of mice engrafted with CD33 KO HSPCs compared to controls, showing that the CD33 KO HSPCs and their myeloid progeny are indeed resistant to CD33-targeted therapy ( Figure 6D ).
The presence of CD33+ AML has the potential to stimulate CART33 proliferation and activation and thus cause bystander myelotoxicity. Therefore, we further interrogated the resistance of CD33 KO HSPCs by injecting mice engrafted with control or CD33 KO HSPCs with Molm14, a CD33+ AML cell line. We (C) Cells from the infusion product were plated in MethoCult, and individual colonies were harvested after 14 days. Each CFU colony was analyzed by PCR and sequencing of the CD33 gRNA targeted region. Percentage of CFUs with heterozygous (HT) and homozygous (KO) mutations were scored. confirmed engraftment of Molm14 by bioluminescent imaging and then treated the mice with CART33 ( Figure 6E ). Leukemia responded to CART33 treatment, as expected in all mice (Figure 6F) . Importantly, we again found rapid clearance of CD33+ cells leading to myeloablation of non-leukemic human cells in the control HSPC mice, while mice engrafted with CD33 KO HSPCs continued to sustain differentiated human myeloid cells and HSPCs despite clearance of leukemic cells ( Figures 6G-6I ). These studies show that CD33 KO HSPCs can be used to circumvent the myeloid toxicity of potent CD33-targeted therapy while still permitting persistent anti-tumor efficacy.
DISCUSSION
Our results provide the first proof of principle that a leukemiaspecific antigen can be synthesized by removal of a shared antigen from normal tissue. Specifically, we have shown that the combination of CD33 KO HSPCs with CART33 can generate a functional hematopoietic system that allows specific targeting of AML. The recent regulatory approvals of anti-CD19 CAR T for B cell malignancies has accelerated the development of CAR T cell therapies for other malignancies, but tumor specificity remains a major challenge. The approach we have proposed here can be viewed as a next-generation hematopoietic stem cell transplant, delivering both anti-leukemic T cells as well as HSPCs resistant to CART33, followed by definitive therapy with CART33 to ensure disease eradication and potent targeted immunosurveillance. CD33 has been pursued as a target for AML for 30 years, culminating in the recent re-approval of gemtuzumab, a toxin-conjugated anti-CD33 monoclonal antibody (Appelbaum and Bernstein, 2017) . We postulate that the use of CAR T cell therapy against CD33 will lead to higher response rates, analogous to the situation with anti-CD19 CAR T cells. We anticipate that our strategy could be rapidly translated to the clinic. Since patients in morphologic remission of AML may harbor otherwiseundetectable leukemic cells, we would obviate the possibility of inadvertently gene editing residual AML cells by generating the gene-edited HSPCs and CAR T cells from allogeneic healthy donors. Patients would undergo conditioning and infusion of allogeneic donor-derived CD33 KO HSPCs followed by administration of CART33 from the same donor.
We could not demonstrate a specific role for CD33 in myeloid differentiation or function in vitro or in vivo in human-murine xenografts or in macaques, with the caveat that we achieved relatively low-level gene editing in the NHPs. Our work contrasts with previous studies, where CD33 was demonstrated to have a constitutive inhibitory effect on myeloid cells through its immunoreceptor tyrosine-based inhibitory motif (ITIM) signaling domain (Ishida et al., 2014; Paul et al., 2000; Taylor et al., 1999; Ulyanova et al., 1999) . One explanation for this discrepancy could be that while CD33 does have a suppressive function, other inhibitory cell surface receptors can compensate for loss of CD33. For example, multiple receptors within the CD33-related siglec family are also expressed on myeloid cells and have overlapping functions (Cao and Crocker, 2011; Nguyen et al., 2006) , suggesting functional degeneracy within this group of proteins. In addition to our findings, the absence of any discernable abnormalities in CD33-deficient mice (Brinkman- Van der Linden et al., 2003) and the existence of humans with homozygous loss of CD33 also indicate that loss of CD33 may be well tolerated. Nonetheless, we cannot definitively exclude the possibility of occult functional defects in CD33 KO myeloid cells that may manifest when this therapy is extended to human subjects and followed long term, or if patients encounter a specific inflammatory stimulus. Therefore, translation of this approach to humans will have to be undertaken carefully.
Gene-edited HSPCs are being investigated for a variety of genetic diseases, utilizing a number of nuclease platforms, including zinc-finger nucleases, TALENS, and most recently, CRISPR/Cas9. We developed a CRISPR/Cas9 gene-editing protocol resulting in consistent and sustained non-homologous end joining (NHEJ)-mediated disruption of the CD33 gene, resulting in efficient homozygous KO and near-complete loss of CD33 (G) Co-engraftment of AML does not impair the survival of CD33-negative myeloid cells in vivo after CART33 treatment in the peripheral blood (top; one-way ANOVA), spleen, and bone marrow (bottom; unpaired t test). (H) Peripheral blood CD33 levels decline after CART33 treatment in both cohorts of mice, resulting in undetectable levels of CD14+ cells in the control mice, while CD14+ cells persist in CD33 KO HSPC-engrafted mice (shown is one representative cohort of mice, single donor, n = 4 per group). (I) Bone marrow human stem and progenitor cells continue to survive CART33-mediated attack, even in the setting of co-existing AML (unpaired t test). All data are represented as means ± SD. ns, not significant (p > 0.05); **p < 0.01; ***p < 0.001; ****p < 0.0001. cell surface expression on human HSPCs and myeloid progeny. Longitudinal tracking of surface CD33 protein expression and mutations in CD33 showed that the levels of deletion were stable over time, including in long-term repopulating HSCs. In RM HSPCs, we found that CD33 KO was more difficult to achieve compared with human HSPCs, but we were able to demonstrate low-level CD33-myeloid cells and bone marrow HSPCs for up to 17 months. Of note, in a previous NHP model using zinc-finger nucleases to disrupt CCR5, levels of gene disruption decreased from 40% early post transplant to 3%-5% at 6 months (Peterson et al., 2016) , concordant with prior reports that long-term HSCs are less susceptible to nuclease-mediated editing than shortterm progenitors (Genovese et al., 2014) . The unremarkable recovery course in the RM after autologous CD33 KO HSPC transplant was comparable with that seen after autologous transplantation of lentivirally transduced HSPCs, an approach that has already accumulated several decades of clinical experience. The CD33 KO RM model demonstrates for the first time that CRISPR/Cas9 technology can be utilized for genome engineering in a clinically relevant large animal model with significantly enhanced biallelic gene-editing efficiency compared with previously published NHP data.
The mitigation of hematologic toxicity from CART33 requires sufficient CD33 KO HSPCs to sustain myelopoiesis. The average level of long-term engrafted human CD33À myeloid cells produced within the human hematopoietic compartment in NSG mice was approximately 75%. These levels sustained normal numbers of myeloid cells in engrafted NSG mice following CART33 administration and would be predicted to be sufficient in humans based on the ability of even single HSPCs to sustain hematopoiesis in preclinical studies (Notta et al., 2011) and the observation that only a few thousand clones are required for stable multilineage hematopoiesis in patients undergoing HSPC gene therapy (Biasco et al., 2016) . However, in a clinical trial, we would endeavor to infuse at least 2x10 6 /kg CD33-deficient HSPCs, as this should provide a safe margin for engraftment and hematopoiesis (based on the lower limit of acceptable cells for bone marrow transplantation and assuming that none of the CD33-sufficient HSPCs remain after CART33). Finally, extensive evaluation of off-target activity failed to reveal sites of potentially critical genotoxicity occurring in CD33 KO HSPCs. However, this does not exclude the possibility of novel off-target activity occurring due to human genetic variation (Scott and Zhang, 2017; Tsai et al., 2017; Yang et al., 2014) or important consequences arising from mutations in genomic sites hitherto classified as benign. Therefore, individual assessment of genotoxicity risks and close monitoring post therapy will be essential during clinical translation.
Antigen-negative escape has been seen after anti-CD19 CAR treatment of acute lymphoblastic leukemia (ALL) (Sotillo et al., 2015) and could potentially occur after successful treatment of AML with the approach proposed here. If this occurs in clinical trials, we could develop a multiplex editing approach to allow simultaneous targeting of multiple antigens. More broadly, this work represents a significant advance in the field of antigen-specific immunotherapy by providing a pathway to avoid on-target off-tumor toxicity when a tumor-specific target is lacking. While our investigations have focused on CD33, this strategy could be extended to other cell-surface antigens or to other forms of antigen-specific immunotherapy, such as monoclonal antibodies, antibody-drug conjugates, or bi-specific T cell engagers, thus widening the therapeutic index of a variety of treatment modalities in AML.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell lines
The Molm14 cell line was obtained from Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); the cell line was established from a 20 year old male. Cells were cultured in RPMI media with 10% fetal calf serum, penicillin and streptomycin. Molm14 cells were lentivirally transduced with luciferase/GFP under the control of the EF1a promoter and sorted to 100% GFP+ for mouse experiments. The LCL8664 rhesus macaque cell line was obtained from the American Type Culture Collection (ATCC); it was derived from a 5 year old male. Cells were cultured in RPMI media with 10% fetal calf serum, penicillin and streptomycin.
Primary human CD34+ cells G-CSF mobilized peripheral blood samples were obtained from left-over clinical specimens according to a University of Pennsylvania IRB-approved consent form for clinical hematopoietic stem/progenitor cell donation. Human subjects were de-identified and thus age and sex information are not available. CD34+ selection was performed using the CD34 Microbead Kit (Miltenyi Biotec, , and purity was confirmed by flow cytometry to be > 95%. Cells were cultured in StemSpan SFEM (Stem Cell Technologies, 09650) supplemented with human cytokines (SCF 100ng/ul, Flt3 ligand 100ng/ul, TPO 50ng/ul, IL-6 50ng/ul, all purchased from Peprotech).
Primary human T cells
Autologous peripheral blood mononuclear cells remaining from the G-CSF mobilized peripheral blood donors after CD34+ cell selection were expanded in vitro using anti-CD3/CD28 Dynabeads (Life Technologies) in X-Vivo 15 media with 5% human serum, penicillin, streptomycin and glutamax. T cells were transduced with lentivirus containing the CAR33 construct as previously described (Kenderian et al., 2015) . The human CD33 scFv was derived from the gemtuzumab ozogamicin antibody (clone P67.6), and the light and heavy chains were cloned into the murine CART19 plasmid vector (Milone et al., 2009 ), a third generation lentiviral vector in which the CAR is expressed under control of the EF-1a promoter. The CAR construct uses a light-to-heavy orientation of the scFv, followed by the human CD8 hinge and transmembrane, 4-1BB costimulatory domain and CD3zeta intracellular signaling domain. Lentivirus was generated by transient transfection of 293T cells using Lipofectamine 2000 (ThermoFisher Scientific, Cat#11668500). T cells were activated with CD3/CD28 Dynabeads (ThermoFisher Scientific, Cat#11132D) at a 1:3 ratio, followed by transduction with lentivirus 1 day after stimulation at a multiplicity of infection of 3. T cells were grown for 10-14 days prior to cryopreservation. Prior to all experiments T cells were thawed and rested at 37 C for 4-16 hours.
Xenogeneic mouse transplantation model
Male and female 8-12 week old NOD-SCID-IL2rgÀ/À (NSG) mice were purchased from Jackson laboratories or bred in-house. All experimental protocols were approved by the Institutional Animal Care and Use Committee at the University of Pennsylvania. Mice were maintained in dedicated BSL-2 animal barrier spaces. Age and sex-matched animals were randomly assigned to experimental groups; no gender-specific influences were detected in the experimental results. 1-5 3 105 control or gene-edited human CD34+ cells were infused by tail vein injection into the mice after prior conditioning with busulfan 30mg/kg intraperitoneally. Mice were evaluated by serial retro-orbital bleeding. Mice were also injected with Molm14 (1x106 cells) and/or autologous CAR T cells (5x106 cells) after CD34+ cell engraftment was confirmed (range: 4-12 weeks post-CD34+ cell injection). After Molm14 injection, mice underwent weekly bioluminescent imaging using a Xenogen IVIS-200 Spectrum camera. Images were acquired and analyzed using Living Image version 4.4 (Caliper LifeSciences, PerkinElmer).
Rhesus macaque animal care and oversight All rhesus macaques were housed, handled and underwent procedures conforming to all regulatory standards, and as specified in a protocol approved by the National Heart, Lung and Blood Institute Animal Care and Use Committee. Both ZL38 and ZL33 were male, three years of age (older juveniles just before sexual maturity) at the time of transplantation ( Figure 4B ). They were heathy and specific pathogen free (SPF) at the time of initiation of transplantation procedures. Neither had been previously enrolled in any other experimental study, undergone prior procedures, or been treated with any medications other than for routine clinical care. Animals were visually monitored daily and underwent quarterly full physical exams. Monitoring of complete blood counts and serum chemistries were monitored at least three times a week following transplantation until complete recovery, and then at least quarterly.
Rhesus macaque mobilization, HSPC collection and autologous transplantation procedures
At least one week prior to HSPC collection, an indwelling venous catheter was placed surgically into the internal jugular vein and tunneled under the skin to an exit site between the shoulder blades. This catheter remains in place until the animal recovers normal blood counts and activity post-transplantation, and is used for administration of medications and blood transfusions, blood drawing, and for apheresis.
Rhesus macaque Mobilization, HSPC collection, and immunoselection were performed as previously described (Donahue et al., 2005; Wu et al., 2014) . Briefly, HSPC mobilization was performed via administration of G-CSF (Amgen) 15 ug/kg/day subcutaneously (SC) for 6 days, and AMD3100 (Sigma) 1 mg/kg SC on day 5 and day 6, the days of apheresis, 2-4 hours before apheresis was initiated. Apheresis was performed using a Fenwal CS-3000 cell separator (no longer manufactured), using a saphenous vein temporary catheter as an inlet port and the central line catheter as an outlet port. Apheresis was performed for 2 hours on days 5 and 6 to generate a mononuclear cell products of 35-45 mL each. CD34+ immunoselection of the concentrated mononuclear cell products was performed using the anti-mouse IgM MicroBeads (Miltenyi Biotec, ) and the anti-CD34 hybridoma clone 12.8 (a murine IgM anti-human CD34 cross-reactive with rhesus CD34). The antibody was derived at the Fred Hutchinson Cancer Center, Seattle, WA and is not commercially-available, but access can be arranged through Dr. Irwin Bernstein at the Fred Hutchinson Cancer Center.
After completion of HSPC collection, fractionated total body irradiation (TBI) at a dose of 5Gy rads daily for two days for a total dose of 10Gy was given at a dose rate of 0.5Gy/minute, using a cobalt source located at the Armed Forces Radiobiology Research Institute (Bethesda, MD). Following the 2nd dose of TBI, edited CD34+ cells (see below) were washed, resuspended in PBS/2% FBS/Heparin (10U/ml) and infused via the central line.
METHOD DETAILS
DNA/RNA Methods Guide RNA design and production Human codon optimized Cas9 expressed under the T7 promoter was kindly provided by Dr. Yangbing Zhao, and Cas9 mRNA was in vitro transcribed using the mMessage mMachine T7 Ultra kit (Ambion, AM1345). Cas9 protein was purchased from PNA Bio (CP02).
The human CD33-targeting gRNA was obtained by screening the top 5 gRNAs previously reported to have high KO efficiency for CD33 (Doench et al., 2014) . Full length and truncated gRNA sequences are as follows:
The control EMX1-targeting gRNA was previously reported (Cong et al., 2013) ; sequence is as follows: 5 0 -GAGTCCGAGCAGAA GAAGAA-3 0 . All gRNAs were generated using the pUC57-sgRNA expression vector (Addgene plasmid #51132) using overlapping DNA oligonucleotides to generate the gRNA insert; cloning was performed using standard molecular biology techniques. The gRNAs were in vitro transcribed using the TranscriptAid T7 High Yield Transcription Kit (Thermo Fisher Scientific, #K0441). RNA was purified using the RNeasy Mini Kit (QIAGEN, 74104). Truncated gRNA4 was found to be most efficacious and was used for all subsequent experiments.
The rhesus macaque CD33-targeting gRNA E2 was selected due to its homology to the gRNA used for human, as it differs by only one nucleotide. The E3 gRNA was designed using Benchling (https://benchling.com); gRNAs with high on-target scores were screened in a rhesus macaque cell line, LCL8664, and E3 was identified as having high efficacy at generating mutations in the CD33 gene as determined by DNA PCR and TIDE analysis. Single-stranded oligodeoxynucleotide (ssODN) design We added a ssODN to the electroporation to increase the frequency of knockout mutations. The ssODN was designed to have 99 base pair homology arms around the Cas9 cut site of the CD33 gene, and an A nucleotide insertion that generates a frameshift mutation and premature truncation of the CD33 protein. The ssODN was ordered from IDT (Integrated DNA Technologies) as an 4nmole Ultramer DNA Oligo. Lyophilized oligo was resuspended in 40ul TE buffer and 1ul was used for each electroporation of 2x106 cells in 500ul OptiMEM. Human CD33 locus DNA analysis Genomic DNA was extracted from the CD34+ cells using the High Pure PCR Template Preparation Kit (Roche, 11796828001). PCR primer sequences are listed in Table S5 . Surveyor Mutation Detection kit (Transgenomics) was used to detect the presence of mutations and band intensities were analyzed using ImageJ software. PCR amplicons were analyzed by Sanger sequencing and allele modification frequency was calculated using TIDE (Tracking of Indels by Decomposition) software available at https://tide.nki.nl. Rhesus macaque CD33 locus DNA analysis Genomic DNA from hematopoietic cells was extracted using the DNeasy Blood & Tissue kit (QIAGEN, Germantown, MD) . Deletions between gRNAs E2 and E3 were detected by PCR amplification using F1 and R2, then quantified with a digital droplet PCR (ddPCR) (Bio-Rad) following the manufacturer's instructions. Briefly, genomic DNA from neutrophils was digested by HindIII (NEB) and diluted to 5ng/ul. Each reaction included 10 mL of 2X ddPCR Supermix for probes (no dUTP), 1 mL of CD33 deletion primer/probe mix (FAM), 1 mL of CD33 distal primer/probe mix (HEX), and 30-100 ng of genomic DNA. The samples were processed using the QX200 Droplet Digital PCR system, and the CD33 deletion rate was calculated with the QuantaSoft software (Bio-Rad). All primer sequences are listed in Table S5 .
Human Cell Methods
Cell line electroporation An AML cell line, Molm1, was used for human gRNA screening. Cells were washed once and resuspended in Opti-MEM. Cas9 mRNA 10ug was added to cell suspension and electroporated with the BTX ECM 830 Square Wave Electroporation System (Harvard Apparatus) using a single pulse of 400V and 5msec. Cells were incubated at 32 C overnight and re-electroporated with gRNA 5ug the next day using the same machine and settings. Cells were kept at 32 C until the following day, after which they were cultured at 37 C until analysis. Human CD34+ cell electroporation Cas9 protein and gRNA were mixed and incubated at room temperature for 10 minutes prior to electroporation. CD34+ cells were washed and resuspended in Opti-MEM and electroporated with the Cas9 ribonucleoprotein complex using the BTX ECM 830 Square Wave Electroporation System (Harvard Apparatus) with a single pulse of 400V and 5msec. 10ug of Cas9 and 5ug of gRNA was used for 2x106 CD34+ cells in 750ul total volume. After electroporation, cells were incubated at 32 C until the following day, after which they were cultured at 37 C until analysis. In vitro human CD34+ cell differentiation CD34+ cells were cultured in IMDM+10% FBS and the following human cytokines: SCF 100ng/ul, Flt3 ligand 100ng/ul, TPO 50ng/ul, IL-6 50ng/ul, GM-CSF 100ng/ul, IL-3 10ng/ul (all purchased from Peprotech). Cells were maintained at 0.5-1x106 cells/ml for 5-7 days prior to analysis.
Morphological analysis
Cytospin specimens of in vitro differentiated control or CD33 KO human CD34+ cells were prepared and immunocytochemistry for CD33 was performed using an anti-CD33 antibody (Novocastra NCL-L-CD33). Staining was done on a Leica Bond-IIITM instrument using the Bond Polymer Refine Detection System (Leica Microsystems DS9800). Heat-induced epitope retrieval was done for 20 minutes with ER1 solution (Leica Microsystems AR9961). Incubation with the anti-CD33 antibody was performed at 1:150 dilution for 15 min. followed by 8 min post-primary step and 8 min incubation with polymer HRP. Endogenous peroxidase was blocked for 5 min, followed by 10 min incubation with DAB (3,3 0 -diaminobenzidine). All procedures were performed at room temperature. Slides are washed three times between each step with bond wash buffer or water. Human colony forming cell (CFC) assay One day after electroporation, 1000 CD34+ cells were plated in 1.1ml of methylcellulose (MethoCult H4435 Enriched, Stem Cell Technologies) on 6 well plates in duplicate and cultured for two weeks, after which colonies were counted and scored. Individual colonies were picked and heat lysed in 40ul of lysis buffer containing 50mM NaOH and 0.2mM EDTA. Samples were heated to 95 C for 20 minutes then cooled down, after which 1ul of 1M TrisCl was added. 2ul of reaction was used for PCR with AccuPrime Pfx SuperMix (Invitrogen, 12344-040) as per manufacturer's instructions. Alternatively, MethoCult wells were solubilized with RPMI media overnight and flow cytometry was performed on single-cell suspensions.
Flow cytometry
In vitro differentiated CD34+ cells were analyzed by flow cytometry 5-7 days after electroporation using the following antibodies: CD11b-FITC (BioLegend, 301329), CD14-APC (BD, 340436), , 304032) , and Live/Dead Fixable Aqua (Life Technologies, L34957).
For in vivo studies assessing human hematopoietic engraftment, the following panel was used: mouse CD45-APC/Cy7 (BioLegend, 103116), human CD45-BV421 (BioLegend, 304032), Live/Dead Fixable Aqua (Life Technologies, L34957), CD19-PE/ Cy7 (BioLegend, 115520), CD3-BV605 (BioLegend, 317322), CD11b-FITC (BioLegend, 301329), CD14-APC (BD, 340436), . For the in vivo studies using Molm14-GFP/luciferase, CD11b-FITC was removed from the panel. For the in vivo studies looking at the effects of G-CSF stimulation, CD66b-PerCP/Cy5.5 (BioLegend, 305107) and CD56-BV711 (BioLegend, 318335) were added. Countbright beads (Invitrogen) were used to quantify cell numbers.
Analysis of bone marrow human HSPC subsets was performed using the following panel: mouse CD45-APC/Cy7 (BioLegend, 103116), human CD45-BV421 (BioLegend, 304032), Live/Dead Fixable Aqua (Life Technologies, L34957), lineage-FITC (Thermo Fisher Scientific, 22-7778-72), CD34-APC (BioLegend, 343608), CD38-BV711 (BioLegend, 303528), . All flow cytometry was performed on a BD Fortessa, and analysis was performed using FlowJo X10. Intracellular cytokine assay of human myeloid cells Cells were incubated with either monensin (BioLegend, 420701) or monensin and LPS for 4 hours at 37 C. Subsequently, cells were harvested and surface staining with CD33-PE was performed, followed by fixation with Invitrogen Fixation Medium A (GAS001S5) for 15 minutes. Cells were then incubated for 20 minutes with Permeabilization Medium B (GAS002S5) containing the following antibodies: MIP1b-PE/Cy7 (BD PharMingen, 560687), IL-8-AF488 (BioLegend, 511412) , and TNFa-AF700 (BioLegend, 502928).
Phagocytosis assay
In vitro differentiated control or CD33 KO human myeloid cells were incubated with pHrodo green E. coli bioparticles (Thermo Fisher Scientific, P343666) for 1 hour at 37 C. Cells were then washed once with Flow Buffer (PBS with 1% FBS and 0.1% sodium azide) and stained with and Live/Dead Fixable Aqua (Life Technologies, L34957) for 15 minutes at room temperature. Cells were then washed again with Flow Buffer and acquired by flow cytometry to quantify phagocytosis. Cellular reactive oxygen species (ROS) analysis In vitro differentiated control or CD33 KO human myeloid cells were stained with CellROX Green Flow Cytometry Assay Kit and evaluated for ROS by flow cytometry according to the manufacturer's protocol (Thermo Fisher Scientific, C10492). In brief, cells were incubated with PMA (5ng/ul) for 15 minutes at 37 C, after which the CellROX reagent was added at a final concentration of 500 nM. Cells were further incubated for 30 minutes at 37 C, then washed once with Flow Buffer and stained with and Live/Dead Fixable Aqua (Life Technologies, L34957) for 15 minutes at room temperature. Cells were then washed again with Flow Buffer, and flow cytometry was performed to quantify ROS. In vivo functional studies of xenografted human HSPC NSG mice engrafted with human CD34+ cells were injected with G-CSF 300ug/kg intraperitoneally twice daily for 2 days at 8 weeks post-transplantation. Frequency of human CD66b+ cells (neutrophils) and CD14+ cells (monocytes) were analyzed before and after G-CSF treatment. At 12 weeks post-transplantation, mice were given 10ug of LPS intraperitoneally, and serum was collected at 0 and 3 hours after injection. Levels of human inflammatory cytokines were measured by BD cytometric bead array, Human Inflammatory Cytokine Kit (BD Biosciences, 551811).
Cytogenetics of human hematopoietic cells
Primary human CD34+ cells electroporated with Cas9 and either control or CD33-targeted gRNA and cultured for 7 days in IMDM+10% FBS with the following human cytokines: SCF 100ng/ul, Flt3 ligand 100ng/ul, TPO 50ng/ul, IL-6 50ng/ul, GM-CSF 100ng/ul, IL-3 10ng/ul. Samples were then treated with colcemid (Life Technologies, 15210-040) and hypotonic solution (homemade solution of EGTA 0.4g (Sigma #4378), HEPES buffer powder 9.6g (Life Technologies, 11344-025), KCl 6.0g in 2L of distilled water; pH adjusted to 7.4 with 10mM NaOH) for 55 minutes, and fixed with a 3:1 methanol/acetic acid solution. Slides were prepared and G-banding was performed using trypsin-Wright staining (Trypsin-EDTA: Life Technologies, 15400-054; Wright stain stock solution: add 3g wright stain powder (Sigma, W0625-25 g) to 1L methanol; Wright stain working solution: add 1ml stock solution to 3ml pHydrion 6.8 buffer working solution). Metaphases were analyzed using Cytovision chromosome analysis software (Leica Biosystems) and the results were described according to the International System for Human Cytogenetic Nomenclature (ISCN 2016) . A clone is defined by conventional cytogenetics as the presence of at least two cells with the same chromosome gain or structural rearrangement, or at least three cells with the same chromosome loss. Mass cytometry analysis of human hematopoietic cells In vitro differentiated control or CD33 KO human HSPC were generated from three normal donors and cultured in cytokine-deplete media (1:32 dilution of differentiation media with cytokine-free IMDM) overnight prior to the assay. Cells were incubated with cisplatin at 50 mM concentration for 1 minute at room temperature for viability staining, then washed and resuspended in cytokine-deplete media. Cells were divided into 10 groups and following cytokines were added to each: none (basal), TPO (50ng/ml), G-CSF (20ng/ml), GM-CSF (20ng/ml), IFNa (5000U/ml), IFNg (20ng/ml), IL-4 (20ng/ml), IL-6 (50ng/ml), PMA/ionomycin (50nM and 1ug/ml each), LPS (100ng/ml). Cells were incubated at 37 C for 15 minutes after which they were immediately fixed by addition of 1/10th volume of 16% paraformaldehyde (PFA) for 10 minutes at room temperature. Cells were then snap frozen in PBS with 0.5% FBS, 0.02% sodium azide and 10% DMSO and stored at À80 C. Cells were thawed at 4 C and then washed once with cell staining media (CSM; 1 3 PBS with 0.5% BSA and 0.02% sodium azide). Cells were then barcoded in groups of 20 cell samples from each donor (2 million cells from each of the 10 stimulation conditions for the control and CD33 KO cells) using a previously described protocol (Zunder et al., 2015) . Briefly, cells were washed twice in PBS at 4 C followed by a 15 minute incubation with palladium barcoding reagent (Fluidigm); the barcoding incubation (and all subsequent steps unless otherwise noted) were performed at room temperature. This barcoding protocol permanently labels each of the 20 samples with a unique combination of 3 of the 6 stable Pd isotopes which allows the cells from each sample to be identified. All 20 samples from each donor were then washed three times in CSM and combined into a single tube for antibody staining and mass cytometry analysis. Mass cytometry staining of the 40 million combined cells was performed in a staining volume of 2mL for 50 minutes at room temperature with gentle agitation using separate staining steps for the surface antigens and intracellular antigens. The antibodies utilized for staining are listed in Table S2 . Antibodies were either purchased from Fluidigm with metal tags attached, or were metal tagged using the Fluidigm MaxPar X8 polymer kit according to the manufacturer's protocol. After each staining step, cells were washed twice in CSM. After surface staining, cells were fixed with 1.5% PFA and then permeabilized with 100% methanol for 15 minutes at À20 C prior to the intracellular stain. After completion of intracellular staining cells were washed twice in CSM and then incubated in Irridium intercalator solution (PBS with a 1:5,000 dilution of the iridium intercalator pentamethylcyclopentadienyl-Ir(III)-dipyridophenazine [Fluidigm] and 1.5% PFA) at 4 C for 16-72 hours prior to analysis. Prior to analysis excess intercalator solution was removed with one CSM wash and two washes in pure water. Cells were then resuspended in pure water at a concentration of approximately 1 million per mL and mixed with mass cytometry measurement standard beads (Fluidigm). Cell events were acquired on a Helios mass cytometer (Fluidigm) at an event rate of 100 to 300 events per second with instrument-calibrated dual-count detection (Ornatsky et al., 2008) . Instrument setting were as follows: noise reduction was on, event duration of 8 to 150, lower convolution threshold of 600, sigma = 3, dual count start = 1. After data acquisition, the mass bead signal was used to correct short-term signal fluctuation during the course of each experiment, and bead events were removed (Finck et al., 2013 ). An average of approximately 800,000 cell events were collected for each sample (range 568,274 -1,029,292 events).
Mass cytometry analysis was performed using Cytobank (https://www.cytobank.org/; (Kotecha et al., 2010) ). SPADE analysis (Qiu et al., 2011) was performed using Cytobank on a sample of approximately 40% of total events (to facilitate computational analysis). Clustering markers are indicated in table S2, down-sampling was performed to a target 8% of total events, clustering was performed to a target of 100 nodes, and fold change was calculated relative to the average of the basal condition of the control cells from the three donors. Approximate immunophenotypic annotations are indicated on each SPADE tree and assignment was performed manually based on a best approximation of the cell immunophenotype and signaling responses; given the artificial nature of the in vitro differentiation, the annotations represent a best estimation and may not be perfectly accurate. Mass cytometry data are plotted on an arcsinh transformed scale.
Rhesus Macaque Cell Methods
Rhesus macaque HSPC electroporation and autologous transplantation Guide RNAs and Cas9 protein were mixed and incubated for 10 minutes before electroporation. Rhesus macaque CD34+ cells were washed with phosphate buffered saline (PBS) and resuspended in Opti-MEM. Subsequently, the cell suspension was mixed with the Cas9 RNP, then electroporated using the BTX ECM 830 Square Wave Electroporation System (Harvard Apparatus) with a single Off-target evaluation: In silico sites Off-targets sites were selected based on two web tools: crispr.mit.edu and CCTop (https://crispr.cos.uni-heidelberg.de/). We selected the top 5 coding sites and the top 3 non-coding sites from each web tool that were predicted to have off-target activity based on sequence homology to the CD33-targeting gRNA. We PCR amplified these off-target loci from genomic DNA extracted from CD34+ cells treated with CRISPR/Cas9, using 5 matched control and CD33 KO donors. PCR products were designed to be 385 ± 24bp around the gRNA cut site. PCR products from each donor were pooled and libraries were generated using NEBnext. Sequencing was performed on the MiSeq 500 (Illumina) with 250bp paired end reads. Read counts obtained per sample and per target are shown in Table S3 . Point mutations and INDELs were identified through the in-house pipeline. Raw reads (fastq) were mapped to the human reference genome (hg19) using Burrows-Wheeler Aligner (BWA). Low complexity regions (LCRs) were removed from the mapped reads using bedtools and then realigned for the INDEL region by GATK IndelRealigner. GATK BaseRecalibrator was then use to recalibrate the filtered reads based on quality. Point mutations and INDELs were called by the variant caller, VarScan2 limited to the mutations that had an allele frequency > 0.1%, a minimum read depth > 8 and existence only in CD33 KO samples. The variants were then annotated by the ANNOVAR. Sequences with indels of R 1 bp located within 5 bp of the predicted Cas9 cut site on either side were considered CRISPR/Cas9 induced genome modifications. CIRCLE-seq Genomic DNA was isolated using Gentra Puregene Kit (QIAGEN) according to manufacturer's instructions. CIRCLE-seq was performed as previously described (Tsai et al., 2017) . Briefly, purified genomic DNA was sheared with a Covaris E200 instrument to an average length of 300 bp. The fragmented DNA was end repaired, A tailed and ligated to a uracil-containing stem-loop adaptor, using KAPA HTP Library Preparation Kit PCR Free (KAPA Biosystems). Adaptor ligated DNA was treated with Lambda Exonuclease (NEB) and E. coli Exonuclease I (NEB) and then with USER enzyme (NEB) and T4 polynucleotide kinase (NEB). Intramolecular circularization of the DNA was performed with T4 DNA ligase (NEB) and residual linear DNA was degraded by Plasmid-Safe ATP-dependent DNase (Epicenter). In vitro cleavage reactions were performed with 125 ng of Plasmid-Safe-treated circularized DNA, 90 nM of SpCas9 protein (NEB), Cas9 nuclease buffer (NEB) and 90 nM of in vitro transcribed gRNA, in a 50 mL volume. Cleaved products were A tailed, ligated with a hairpin adaptor (NEB), treated with USER enzyme (NEB) and amplified by PCR with barcoded universal primers NEBNext Multiplex Oligos for Illumina (NEB), using Kapa HiFi Polymerase (KAPA Biosystems). Libraries were quantified by droplet digital PCR (Bio-Rad) and sequenced with 150 bp paired-end reads on an Illumina MiSeq instrument. CIRCLE-seq data analyses were performed using open-source CIRCLE-seq analysis software (https://github.com/tsailabSJ/circleseq). Off-target evaluation: CIRCLE-seq sites We selected the top 7 sites with highest CIRCLE-seq read count (c10orf20, DGKG, EPS8, ALDH3B1, RN7SL601P, DAPK2, TSPAN2) and all sites with 3 or less mismatches to the on-target site to validate in primary CD33 KO cell samples. PCR amplification, sequencing and analysis was performed in a similar fashion to the in silico predicted off-target evaluation. Read counts obtained per sample and per target are shown in Table S4 . Targeted deep sequencing of rhesus macaque CD33 locus Next generation sequencing was conducted using the Miseq sequencer (Illumina) with 300bp paired end reads for indel identification. PCR products were amplified using F1 and R1 for the gRNA E2 targeting region and F2 and R2 for the gRNA E3 targeting region as described above. Sequencing depth was generally between 50,000 -300,000 reads/gRNA target site. To account for single nucleotide polymorphisms unique to individual monkeys, a consensus sequence for each targeted gene in each edited monkey was generated from the pre-transplantation sequencing data with a custom Python pipeline. CRISPResso (http://crispresso.rocks) was then used to align sequencing reads from various time points to the appropriate consensus and to quantify the number of reads for each unique sequence. Sequences that, at all other time points, do not change appreciably in frequency (< j0.1%j) compared to the precut sample and sequences that only appear once across all time points were excluded from further analysis with custom Python code. Custom Python code was also used to apply an 18 bp window positioned where the gRNA complimentary base pairs with the consensus sequence. Heatmaps were then generated using a custom R application.
QUANTIFICATION AND STATISTICAL ANALYSIS
All statistical analyses were performed using GraphPad Prism 6. Unpaired Student's t test was performed for pairwise comparisons and one-way analysis of variance (ANOVA) with Bonferroni's multiple comparison post-test for three or more groups, as indicated.
DATA AND SOFTWARE AVAILABILITY
RNA-seq data has been deposited in NCBI's Gene Expression Omnibus and are accessible through GEO Series accession number GEO: GSE113670 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE113670).
Custom Python code for Rhesus macaque targeted deep sequencing analysis is available at https://github.com/shirleychen2/ crispr_analysis. A) SPADE diagram of a representative donor showing CD33 expression of in vitro differentiated control and CD33 KO primary CD34+ cells. SPADE clustering was performed on all 6 samples (3 donors, each with control and CD33 KO) simultaneously to generate a single tree structure for all samples, and all events from each sample were mapped to the common tree structure. CD33 expression (as depicted by node color) is globally decreased across all groups in the CD33 KO cells, while differentiation profile (as depicted by node size) is similar to control cells. (B) Heatmaps showing signaling profile of myeloid cell clusters within control and CD33 KO cells in response to external stimuli. In vitro differentiated control and CD33 KO HSPC from three donors were treated with various stimuli (GM-CSF, G-CSF, IFNa, IFNg, IL-4, IL-6, LPS, PMA/ionomycin, and TPO), and mass cytometry was performed with antibodies to 20 surface markers and 10 phosphoproteins for comprehensive analysis of signaling. CD33+ and CD33-cells were analyzed separately within the CD33 KO cell population and compared to ungated controls. Groups are defined by the SPADE tree shown in (A). Scaled to arcsinh ratio versus basal of the same donor. One representative donor is shown. (E) Visualization of all on-target and off-target sites detected by CIRCLE-seq in a primary human genomic DNA sample that is identical to donor G in (D) . CIRCLEseq was performed by in vitro digestion of genomic DNA with Cas9/CD33-gRNA; validation by targeted deep sequencing was performed on genomic DNA from cells that underwent the CD33 KO procedure then differentiated in vitro (donors E,G) as outlined in Figure 1E , or differentiated in mice (donor F) as outlined in Figure 2A . 
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